<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2019.4.10252</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-594</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РАЗНОЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MISCELLANEOUS</subject></subj-group></article-categories><title-group><article-title>Сократительная функция миокарда у пациентов с циррозом печени и синдромом избыточного бактериального роста</article-title><trans-title-group xml:lang="en"><trans-title>Myocardial Contractile Function in Patients with Liver Cirrhosis and Syndrome of Bacterial Overgrowth Syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивашкин</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashkin</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>MD, PhD</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">2135833@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Широкова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shirokova</surname><given-names>E. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивашкин</surname><given-names>В. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashkin</surname><given-names>V. T.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плюснин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Plyusnin</surname><given-names>S. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жаркова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zharkova</surname><given-names>M. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Масленников</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maslennikov</surname><given-names>R. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Схиртладзе</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Skhirtladze</surname><given-names>M. R.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маевская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maevskaya</surname><given-names>M. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «3‑й Центральный военный клинический госпиталь им. А. А. Вишневского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>3rd Central Military Clinical Hospital named after A. A. Vishnevsky</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>17</day><month>04</month><year>2019</year></pub-date><volume>59</volume><issue>4</issue><fpage>67</fpage><lpage>73</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/594">https://cardio.elpub.ru/jour/article/view/594</self-uri><abstract><p>Цель исследования. Изучить сократительную функцию миокарда у пациентов с циррозом печени (ЦП) и асцитом при наличии синдрома избыточного бактериального роста (СИБР) и патологической бактериальной транслокации (БТ). Материалы и методы. В исследование были включены 59 пациентов с ЦП различной этиологии класса В и С по классификации Чайлд–Пью. Контрольная группа включала 12 пациентов с ишемической болезнью сердца, осложненной хронической сердечной недостаточностью (ХСН). План обследования включал сбор анамнестических данных, физическое обследование, лабораторные и инструментальные исследования. Диагноз ЦП устанавливали на основании клинической симптоматики и данных инструментального исследования. Тяжесть ЦП и прогноз пациентов оценивали по шкалам Чайлд–Пью и MELD. Оценивали критерии печеночной недостаточности и синдрома системного воспалительного ответа. Тяжесть асцита определяли на основании критериев International Ascites Club (Международный клуб по изучению асцита). СИБР диагностировали с использованием водородного дыхательного теста. Синдром патологической бактериальной транслокации устанавливали на основании измерения в крови липополисахарид-связывающего белка (ЛПС-СБ) и обнаружении ДНК бактерий в асцитической жидкости. Концентрация липополисахарид-связывающего белка в крови больных циррозом печени и здоровых добровольцев определяли методом иммуноферментного анализа (ELISA Human LBP, Нидерланды). Фрагменты ДНК бактерий в асцитической жидкости определяли методом полимеразной цепной реакции. Метод позволяет идентифицировать ДНК E. Coli, Enterobacter, Enterococcus faecalis, Staphylococcus aureus, Streptococcus spp., Pseudomonas aeruginosae, Serratia, Proteus spp. Чувствительность диагностических наборов – 104 КОЕ / мл. Постановка всех реакций осуществлялась в соответствии с инструкциями фирм-изготовителей. Оценку структурно-функциональных параметров миокарда и гемодинамики осуществляли с помощью эхокардиографии. В крови и асцитической жидкости определяли мозговой натрийуретический пептид В-типа. Результаты. В группе из 59 пациентов с ЦП и асцитом у 13 водородный дыхательный тест был отрицательный, у 33 – положительный, у 13 пациентов положительный водородный тест сочетался с наличием СИБР и патологической БТ. Обнаружены низкие концентрации BNP в сыворотке крови и асцитической жидкости (62,5±4,1 и 53,3±4,9 пг / мл соответственно), находящиеся в диапазоне нормальных значений у пациентов с ЦП, по сравнению с показателями у пациентов с ХСН (1820±95,5 и 497,1±39,6 пг / мл соответственно). Сывороточно-асцитический альбуминовый градиент в обеих группах пациентов превосходил значение 1,1 и составил у пациентов с ХСН 1,58±0,13, у пациентов с ЦП – 1,88±0,19. Уровень общего белка в асцитической жидкости у пациентов с ЦП был существенно ниже (1,77±0,1 мг / дл), чем у пациентов с ХСН (4,43±0,35 мг / дл). Вместе с тем у 4 пациентов с ЦП (50 % в группе с СИБР и БТ и 16,7 % от всех пациентов с ЦП) концентрация асцитического белка превышала 2,5 г / дл. Эта находка может расцениваться как  свидетельство умеренной капилляризации синусоидов или как показатель воспалительного раздражения брюшины у отдельных пациентов с БТ. Заключение. Наличие СИБР и патологической БТ не оказывало отчетливого отрицательного влияния на сократительную функцию миокарда.</p></abstract><trans-abstract xml:lang="en"><p>Objective: to study myocardial contractile function in patients with liver cirrhosis and ascites in the presence of bacterial overgrowth syndrome (BOS) and pathological bacterial translocation. Materials and methods. We included in this study 59 patients with Child-Pugh class B and C liver cirrhosis (LC) of various etiology and ascites. Control group comprised 12 patients with ischemic heart disease complicated by chronic heart failure (CHF). Examination included history taking and laboratory and instrumental investigation. LC was diagnosed basing on clinical symptoms and instrumental studies. Child-Pugh and MELD scores were used for assessment of LC severity and prognosis. International ascites club grading system was used for evaluation of severity of ascites. Hydrogen breath test was applied for diagnosing BOS. Syndrome of pathological bacterial translocation was established based on blood levels of lipopolysaccharide-binding protein and detection of bacterial DNA in ascitic fluid. Structural-functional parameters of the myocardium and hemodynamics were assessed by echocardiography. Brain natriuretic peptide (BNP) concentration was measured in blood serum and ascitic fluid. Results. In 13 of 59 patients with LC the hydrogen breath test was negative, in 33 positive and in 13 patients the positive hydrogen test was combined with the presence of BOS and pathological bacterial translocation. Blood serum and ascitic fluid BNP concentrations in LC patients were low and within normal limits (62.5±4.1 and 53.3±4.9 rg / ml, respectively), what contrasted with high BNP concentrations in patients with CHF (1820±95.5 and 497.1±39.6 rg / ml, respectively). Total protein level in ascitic fluid also was significantly lower in patients with LC than in patients with CHF (1.77±0.1 and 4.43±0.35 mg / dL, respectively). The serum-ascitic albumin gradient (SAAG) in both groups of patients exceeded 1.1 (1.58±0.13 in patients with CHF and 1.88±0.19 in patients with LC). Conclusions. In patients with liver cirrhosis the presence of BOS and bacterial translocation did not produce a distinct negative impact on contractile function.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>цирроз печени</kwd><kwd>сердечная недостаточность</kwd><kwd>синдром избыточного бактериального роста</kwd><kwd>сывороточно-асцитический альбуминовый градиент</kwd><kwd>мозговой натрийуретический пептид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver cirrhosis</kwd><kwd>heart failure</kwd><kwd>bacterial overgrowth syndrome</kwd><kwd>serum-ascitic albumin gradient</kwd><kwd>brain natriuretic peptide (BNP)</kwd><kwd>proBNP</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Runyon BA. The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites. Annals of Internal Medicine. 1992;117(3):215. DOI: 10.7326/0003-4819-117-3-215</mixed-citation><mixed-citation xml:lang="en">Runyon BA. The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites. Annals of Internal Medicine. 1992;117(3):215. DOI: 10.7326/0003-4819-117-3-215</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. The Lancet. 2003;362(9380):316–22. DOI: 10.1016/S0140-6736(03)13976-1</mixed-citation><mixed-citation xml:lang="en">de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. The Lancet. 2003;362(9380):316–22. DOI: 10.1016/S0140-6736(03)13976-1</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility: Current Opinion in Critical Care. 2004;10(5):336–41. DOI: 10.1097/01.ccx.0000135513.26376.4f</mixed-citation><mixed-citation xml:lang="en">Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility: Current Opinion in Critical Care. 2004;10(5):336–41. DOI: 10.1097/01.ccx.0000135513.26376.4f</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Maisel A, Mueller C, Adams K, Anker SD, Aspromonte N, Cleland JGF et al. State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure. 2008;10(9):824–39. DOI: 10.1016/j.ejheart.2008.07.014</mixed-citation><mixed-citation xml:lang="en">Maisel A, Mueller C, Adams K, Anker SD, Aspromonte N, Cleland JGF et al. State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure. 2008;10(9):824–39. DOI: 10.1016/j.ejheart.2008.07.014</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassel BW et al. Cirrhotic Cardiomyopathy. Journal of the American College of Cardiology. 2010;56(7):539–49. DOI: 10.1016/j.jacc.2009.12.075</mixed-citation><mixed-citation xml:lang="en">Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassel BW et al. Cirrhotic Cardiomyopathy. Journal of the American College of Cardiology. 2010;56(7):539–49. DOI: 10.1016/j.jacc.2009.12.075</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Henriksen JH. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52(10):1511–7. DOI: 10.1136/gut.52.10.1511</mixed-citation><mixed-citation xml:lang="en">Henriksen JH. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52(10):1511–7. DOI: 10.1136/gut.52.10.1511</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients: BNP in cirrhosis. Journal of Gastroenterology and Hepatology. 2005;20(7):1115–20. DOI: 10.1111/j.1440-1746.2005.03906.x</mixed-citation><mixed-citation xml:lang="en">Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients: BNP in cirrhosis. Journal of Gastroenterology and Hepatology. 2005;20(7):1115–20. DOI: 10.1111/j.1440-1746.2005.03906.x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura P-J et al. A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology. 2001;34(1):46–52. DOI: 10.1016/S0168-8278(00)00011-8</mixed-citation><mixed-citation xml:lang="en">Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura P-J et al. A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology. 2001;34(1):46–52. DOI: 10.1016/S0168-8278(00)00011-8</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine. 1992;20(6):864–74. PMID: 1597042</mixed-citation><mixed-citation xml:lang="en">American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine. 1992;20(6):864–74. PMID: 1597042</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison’s principles of internal medicine. 15 ed. -New York: McGraw-Hill; Редакторы: Braunwald E, Harrison TR. 2001. 91–94pp. ISBN 978-0-07-007272-5</mixed-citation><mixed-citation xml:lang="en">Harrison’s principles of internal medicine. 15 ed. -New York: McGraw-Hill; Braunwald E, Harrison TR. 2001. 91–94pp. ISBN 978-0-07-007272-5</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Moore KP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(suppl_6):vi1–12. DOI: 10.1136/gut.2006.099580</mixed-citation><mixed-citation xml:lang="en">Moore KP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(suppl_6):vi1–12. DOI: 10.1136/gut.2006.099580</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Moore K. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258–66. DOI: 10.1053/jhep.2003.50315</mixed-citation><mixed-citation xml:lang="en">Moore K. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258–66. DOI: 10.1053/jhep.2003.50315</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rimola A, García-Tsao G, Navasa M, Piddock LJV, Planas R, Bernard B et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Journal of Hepatology. 2000;32(1):142–53. DOI: 10.1016/S0168-8278(00)80201-9</mixed-citation><mixed-citation xml:lang="en">Rimola A, García-Tsao G, Navasa M, Piddock LJV, Planas R, Bernard B et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Journal of Hepatology. 2000;32(1):142–53. DOI: 10.1016/S0168-8278(00)80201-9</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Schiller LR. Evaluation of small bowel bacterial overgrowth. Current Gastroenterology Reports. 2007;9(5):373–7. PMID: 17991337</mixed-citation><mixed-citation xml:lang="en">Schiller LR. Evaluation of small bowel bacterial overgrowth. Current Gastroenterology Reports. 2007;9(5):373–7. PMID: 17991337</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P et al. Recommendations for chamber quantification. European Journal of Echocardiography. 2006;7(2):79–108. DOI: 10.1016/j.euje.2005.12.014</mixed-citation><mixed-citation xml:lang="en">Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P et al. Recommendations for chamber quantification. European Journal of Echocardiography. 2006;7(2):79–108. DOI: 10.1016/j.euje.2005.12.014</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2009;22(2):107–33. DOI: 10.1016/j.echo.2008.11.023</mixed-citation><mixed-citation xml:lang="en">Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2009;22(2):107–33. DOI: 10.1016/j.echo.2008.11.023</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Наследов А.Д. IBM SPSS Statistics 20 и AMOS: профессиональный статистический анализ данных. -СПб: Питер, 2013. -416 с. ISBN 978-5-496-00107-6</mixed-citation><mixed-citation xml:lang="en">Nasledov A.D. IBM SPSS Statistics 20 and AMOS. Professional statistical data analysis. -St. Petersburg: Piter, 2013. -416 p. ISBN 978-5-496-00107-6</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. -М: Медиа Сфера, 2006. -312с. ISBN 978-5-89084-013-4</mixed-citation><mixed-citation xml:lang="en">Rebrova O.Yu. Statistical analysis of medical data. Application software package STATISTICA. -M.: Media Sfera, 2006. -312 p. ISBN 978-5-89084-013-4</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mant J. Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline. Annals of Internal Medicine. 2011;155(4):252. DOI: 10.7326/0003-4819-155-4-201108160-00009</mixed-citation><mixed-citation xml:lang="en">Mant J. Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline. Annals of Internal Medicine. 2011;155(4):252. DOI: 10.7326/0003-4819-155-4-201108160-00009</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bari K. Treatment of portal hypertension. World Journal of Gastroenterology. 2012;18(11):1166–75. DOI: 10.3748/wjg.v18.i11.1166</mixed-citation><mixed-citation xml:lang="en">Bari K. Treatment of portal hypertension. World Journal of Gastroenterology. 2012;18(11):1166–75. DOI: 10.3748/wjg.v18.i11.1166</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Farias AQ, Silvestre OM, Garcia-Tsao G, da Costa Seguro LFB, de Campos Mazo DF, Bacal F et al. Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: A diagnostic accuracy study: Hepatology. Hepatology. 2014;59(3):1043–51. DOI: 10.1002/hep.26643</mixed-citation><mixed-citation xml:lang="en">Farias AQ, Silvestre OM, Garcia-Tsao G, da Costa Seguro LFB, de Campos Mazo DF, Bacal F et al. Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: A diagnostic accuracy study: Hepatology. Hepatology. 2014;59(3):1043–51. DOI: 10.1002/hep.26643</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
